Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces today the scientific communication program for the results of the ARENA-1 clinical development program.
The latest results of the follow-up study of patients with distal Renal Tubular Acidosis (dRTA) treated with ADV7103 will be presented at the following scientific conferences:
- European Renal Association (ERA), June 15-18, 2023 Milan (Italy)
Title: Significant clinical improvement of pediatric and adult patients with distal Renal Tubular Acidosis after 6 years of treatment with Sibnayal®
Authors: Dr. Aurélia Bertholet et al.
Session: Focused Orals 1.1 (June 16)
- European Society of Pediatric Nephrology (ESPN), September 28 to October 1, 2023 Vilnius (Lithuania)
Title: Long-term clinical outcomes in patients with distal renal tubular acidosis after 6 years treatment with Sibnayal®
Authors: Dr. Aurélia Bertholet et al.
Session: Symposium 5 Diagnostics (Oral presentation, September 30)
During the ERA congress, the European Society of Pediatric Nephrology (ESPN) will present the first follow-up analyses of dRTA patients from the European registry.
Title: First interim analysis of the international distal renal tubular acidosis registry
Authors: Dr. Marta Giaccari et al.
Session: Free communication (June 16)
About Advicenne
Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: https://advicenne.com/.
Disclaimer
This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2022 Universal Registration Document filed with the French financial market authority on April 28, 2023 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230613525191/en/
Contacts:
Advicenne
Didier Laurens, CEO
+33 (0)1 87 44 40 17
Email: investors@advicenne.com
Ulysse Communication
Media relations
Bruno Arabian
+33 (0)6 87 88 47 26
Email: barabian@ulysse-communication.com
